Next, they tested the role of CSPG4 mAb in PD-1/PD-L1 blocking capacity of PDL1xCSPG4 BsAb by replacing the CHO.PD-L1/CD3 cells with a CSPG4+/PD-L1+ cancer cell line (the CD3 stimulation of T cells was achieved by pre-treating the cells with BIS1; an EpCAM-directed CD3-agonistic bsAb). This evidence concerns the gene CD274 and cancer.